Ultragenyx Pharmaceutical Inc.

As of June 30, 2026, Ultragenyx Pharmaceutical, Inc. carries a market capitalization of 49.64B, placing it among publicly traded companies globally. Its enterprise value stands at 44.66B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Ultragenyx Pharmaceutical, Inc.'s next confirmed earnings release is scheduled for November 4, 2026.

As of June 30, 2026, Ultragenyx Pharmaceutical, Inc. has 98.60M shares outstanding.

These figures are as of June 30, 2026. The price-to-sales ratio is 4.04, and the price-to-book ratio stands at -9.76.

These figures are as of June 30, 2026. The EV/Sales ratio of 3.56 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 44.66B versus a market cap of 49.64B, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, Ultragenyx Pharmaceutical, Inc. maintains a current ratio of 1.73, meaning it holds 1.7x the short-term assets needed to cover near-term liabilities.

These figures cover the twelve months ended June 30, 2026. Return on assets (ROA) is negative at -45.60, reflecting losses generated across the asset base. The company generates approximately 9.27M in revenue per employee across its workforce of 1,351.75, a quick read on workforce productivity versus industry peers. Inventory turnover of 2.30 indicates how many times Ultragenyx Pharmaceutical, Inc. sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, Ultragenyx Pharmaceutical, Inc. recorded 65.40M in income tax expense. The company reported a pretax loss of -10.17B and -10.24B in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

As of the close on October 14, 2026, Ultragenyx Pharmaceutical, Inc.'s stock has declined approximately 50.96% over the past 52 weeks.

Over the twelve months ended June 30, 2026, Ultragenyx Pharmaceutical, Inc. generated 12.53B in revenue and converted that into -10.24B in net income, yielding earnings per share of -101.83. EBITDA reached -8.65B, while operating income came in at -9.23B.

These figures are as of June 30, 2026. Total book value stands at -5.08B, with working capital of 4.46B providing operational flexibility.

Ultragenyx Pharmaceutical, Inc. produced -8.47B in operating cash flow over the twelve months ended June 30, 2026. After subtracting -157.24M in capital expenditures, free cash flow totaled -8.63B - equivalent to -85.84 per share.

Over the twelve months ended June 30, 2026, Ultragenyx Pharmaceutical, Inc. posted a gross margin of 83.08, reflecting its pricing power and cost economics. The operating margin of -73.64 and net profit margin of -81.70 provide insight into operational efficiency.

These figures cover the twelve months ended June 30, 2026. Free cash flow yield is negative at -17.05: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow.

As of June 30, 2026, Ultragenyx Pharmaceutical, Inc. has an Altman Z-Score of -6.01, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.